SPL-707 is an orally active, selective signal peptide peptidase-like 2a (SPPL2a) inhibitor with an IC 50 of 77 nM for hSPPL2a. SPL-707 inhibits γ-secretase (IC 50 =6.1 μM) and SPP (IC 50 =3.7 μM). SPL-707 has the potential for autoimmune diseases research by targeting B cells and dendritic cells.
SPL-707 (Compound 40) inhibits mouse SPPL2a (IC50=0.18 μM), rat SPPL2a (IC50=0.056 μM) and human SPPL2a (IC50=0.16 μM), human SPPL2b (IC50=0.43 μM) by a high content imaging assay (HCA). has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
SPL-707 (Compound 40; 3-30 mg/kg; orally; b.i.d.; for 11 days) leads to a reduction in B cells and myeloid dendritic cells without affecting γ-secretase activity.
SPL-707 (3 mg/kg of po and 1 mg/kg of iv) has a CL of 6 mL/min?kg, and an AUC of 8787 h?nM.
SPL-707 (1, 3 mg/kg; b.i.d.; first dose at 0 h, second dose at 8 h) achieves full inhibition of CD74/p8 processing in spleen in female Lewis rats. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
参考文献
[1]. Velcicky J, et al. Discovery of the First Potent, Selective, and Orally Bioavailable Signal Peptide Peptidase-Like 2a (SPPL2a) Inhibitor Displaying Pronounced Immunomodulatory Effects In Vivo. J Med Chem. 2018 Feb 8;61(3):865-880.
溶解度数据
In Vitro: DMSO : 100 mg/mL (197.81 mM; Need ultrasonic)配制储备液